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Abstract
Within the field of genetic association studies, detecting disease–genotype associations
is a primary goal. For most diseases, the underlying genetic model is unknown, and we
study seven robust test statistics for monotone disease–genotype association. For a given
test statistic there are many ways to calculate a p-value, but in genetic association studies,
p-value calculations have predominantly been based on asymptotic approximations and on
simulated permutation. We show that when the number of permutations tends to infinity,
the permutation p-value approaches the exact conditional enumeration p-value, and further
that calculating the exact conditional enumeration p-value is much more efficient than per-
forming simulated permutations. We then answer two research questions. (i) Which of the
seven robust test statistics under study are the most powerful for monotone genetic mod-
els? (ii) Based on test size, power, and computational considerations, should asymptotic
approximations or exact conditional enumeration be used for calculating p-values? We have
studied case–control sample sizes with 500–5000 cases and 500–15000 controls, and signific-
ance levels from 5 ·10−8 to 0.05, thus our results are applicable to genetic association studies
with only one genetic marker under study, intermediate follow-up studies, and genome wide
association studies. Our main findings are as follows. If all monotone genetic models are of
interest, the best performance in the situations under study is achieved for the robust test
statistics based on the maximum over a range of Cochrane–Armitage trend tests with dif-
ferent scores and for the constrained likelihood ratio test. For significance levels below 0.05,
for the test statistics under study, asymptotic approximations may give a test size up to
20 times the nominal level, and should therefore be used with caution. Further, calculating
p-values based on exact conditional enumeration is a powerful, valid and computationally
feasible approach, and we advocate its use in genetic association studies.
1 Introduction
In genetic association studies the aim is to detect a possible association between a phenotype
and one or many genetic markers. This can be done for one marker at a time. We will consider
biallelic genetic markers, giving three possible genotypes. For each genetic marker the following
steps can be performed. (i) First an hypothesis test situation is specified. (ii) This guides the
choice of a test statistic. (iii) Then a method to calculate a p-value is chosen. (iv) Finally, the
calculated p-value is compared to a chosen significance level to arrive at a conclusion.
A hypothesis test situation may be formulated as “no association between the disease and
the genetic marker” versus “association between the disease and the genetic marker”. In some
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genetic studies, in particular for monogenic diseases, the effect of the disease allele on the disease
phenotype may be known to follow a specific genetic model, such as dominant, recessive, additive,
or multiplicative (e.g. Camp, 1997). The genetic model can be used as alternative hypothesis
to construct a test statistic tailored to detect this type of disease–genotype association. For
genome-wide association (GWA) studies the underlying genetic model of a disease allele is
seldom known (e.g. Devlin and Roeder, 2004). Therefore, it is desirable to base the statistical
inference on a test statistic that give high power over a wide range of genetic models. These
types of test statistics are commonly referred to as robust test statistics (Freidlin et al., 2002).
We will restrict our attention to performance under what we will call monotone genetic models,
under which the genetic effect of the heterozygous genotype lies between the two homozygous
genotypes. This means that we are not considering overdominant models. The first research
questions we want to address in this presentation is which of the available popular robust test
statistics that are most suitable for use when the underlying genetic model is unknown, but
monotone.
Two approximations that have been used to calculate p-values for disease–genotype associ-
ation are asymptotic methods and simulated permutations (Sladek et al., 2007). We will argue
that exact conditional enumeration yields the same p-values as permutation when the number
of permutations tends to infinity, and is also less computationally intensive than simulated per-
mutations. We will therefore consider asymptotic methods and exact conditional enumeration.
Many other ways of calculating p-values exists, see Langaas and Bakke (2013) for a presentation
of unconditional enumeration methods for discrete distributions suitable for small to moderate
sample sizes.
Exact conditional enumeration is a general method by which the p-value of an outcome is
calculated based on a test statistic and the conditional probabilities of all possible outcomes of
the conditional experiment in question. The most popular use of exact conditional enumeration
is the Fisher exact test. There is a large body of literature on hypothesis testing in 2 × 2 con-
tingency tables, where conditional tests are often found to be less powerful than unconditional
alternatives, as described by Mehrotra et al. (2003) and Lydersen et al. (2009). Our focus is
on disease–genotype association for a biallelic marker in a case–control setting, which means
that the data can be presented in a 2 × 3 contingency table. The conditioning is done on the
column margins, and the conditional probability of an outcome is a trivariate hypergeometric
probability. Due to the less discrete nature of higher order contingency tables, some researchers
have found that the power disadvantage of the conditional test tends to be less pronounced than
for the 2 × 2 contingency table (Mehta and Hilton, 1993). For larger contingency tables exact
conditional enumeration is believed to require substantial computer resources (enumeration and
summation of probabilities) and thus not to be feasible for testing for disease–genotype associ-
ation. We will show that even for large sample sizes, 5000 cases and at least 5000 controls in
a 2 × 3 contingency table, exact conditional enumeration can be performed in a fraction of a
second on a standard computer. Turning to the asymptotic methods, it is known that asymp-
totic methods will not preserve test size in situations where the asymptotic approximation is
poor. The second research question we want to address is therefore whether asymptotic or ex-
act conditional enumeration methods are most suitable to use in terms of power, test size and
computational resources when testing disease–genotype association with a robust test statistic.
In GWA studies multiple testing correction is commonly performed by controlling the
familywise error rate by the Bonferroni method. When a single genetic marker is studied,
a significance level of α = 0.05 is commonly used. For larger candidate studies, or follow-
up studies, with 10–1000 genetic markers under study, significance levels of the order 5 ·
10−3 − 5 · 10−5 may be used. For genome-wide association (GWA) studies with ten thou-
sand to one million genetics markers, significance levels 5 · 10−6 − 5 · 10−8 have been used
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Table 1: Notation for 2× 3 table, case–control data.
Genotype
aa aA AA Total
Case x0 x1 x2 n1
Control y0 y1 y2 n2
Total m0 m1 m2 N
(The Wellcome Trust Case Control Consortium, 2007). Dudbridge and Gusnanto (2008) advoc-
ated using significance level 7.2 · 10−8 for general GWA studies. When we investigate our two
research questions we will study significance levels in the range 5 · 10−2 − 5 · 10−8, and sample
sizes in the range 500–5000 cases and 500–15000 controls.
The presentation is organized as follows. In Section 2 we present notation, data structure,
test statistics, methods for calculating p-values and estimation of power. We then present the
results of a large simulation study to compare the power of different robust test statistics
combined with either the asymptotic method or the exact conditional enumeration method in
Section 3. We discuss in Section 4 and conclude in Section 5.
2 Methods
2.1 Notation and data
We will to some extent adopt the notation of Joo et al. (2009) and Langaas and Bakke (2013).
We assume that genotypes and a dichotomous phenotype (disease) are collected in a case–control
study, and that the genotype data are from biallelic genetic markers with alleles a and A. For
each genetic marker, we assume that A is the high risk allele, and index the three genotypes aa,
aA, and AA, by 0, 1, 2, respectively. Further, for each genetic marker let g0, g1 and g2 be the
genotype frequencies for the three genotypes in the population under study, p0, p1, and p2 the
genotype frequencies of the case population (disease phenotype) and q0, q1, and q2 the genotype
frequencies of the control population.
For each genetic marker we may present the collected data in a 2 × 3 contingency table
(Table 1). The number of cases and controls with genotype i is denoted by xi and yi, respectively,
and the total number of cases and controls with genotype i by mi = xi + yi, i = 0, 1, 2. Let
n1 = x0 + x1 + x2 denote the total number of cases, n2 = y0 + y1 + y2 the total number of
controls, and let N = n1 + n2 = m0 +m1 +m2.
The vectors (x0, x1, x2) and (y0, y1, y2) are considered to be independent and trinomially
distributed with parameters (n1; p0, p1, p2) and (n2; q0, q1, q2), respectively. The probability of
a disease–genotype table with entries z = (x0, x1, x2, y0, y1, y2) for a given set of parameters
θ = (p0, p1, p2, q0, q1, q2) is
Prθ(Z = z) =
n1!
x0!x1!x2!
px00 p
x1
1 p
x2
2 ·
n2!
y0!y1!y2!
qy00 q
y1
1 q
y2
2 . (1)
2.2 Statistical Hypotheses and Genetic Models
Let k be the disease prevalence, and fi be the penetrance, i.e. the conditional probability of
disease given genotype i. Then pik = figi and qi(1 − k) = (1 − fi)gi for i = 0, 1, 2. The
null hypothesis that we will investigate is that the penetrances are equal for the three possible
3
genotypes,
f0 = f1 = f2, (2)
which can be shown to be equivalent to pi = qi for i = 0, 1, 2. Further, denote by λ1 = f1/f0
and λ2 = f2/f0 the genotype relative risks. We define a monotone genetic model to satisfy
f0 ≤ f1 ≤ f2, (3)
or alternatively 1 ≤ λ1 ≤ λ2, which can be shown to be equivalent to p0/q0 ≤ p1/q1 ≤ p2/q2. As
alternative hypotheses we consider monotone genetic models where at least one of the equalities
are strict. Those models can be parameterized by
λ1 = 1− δ + δλ2, (4)
where λ2 > 1 and 0 ≤ δ ≤ 1. The value δ = 0 yields the recessive genetic model, δ = 1/2 the
additive genetic model, and δ = 1 the dominant genetic model. We will refer to the genetic
model with δ = 1/4 as semi-recessive and δ = 3/4 as semi-dominant.
2.3 Test Statistics and Asymptotic Distributions
We now consider test statistics for testing the null hypothesis (2) against the alternative of a
general monotone genetic model (4) or some specified monotone genetic model. The potential
high risk allele is often unknown. Therefore all tests will be two-sided, in the sense that the
conclusion of the test will be the same if the data for each homozygote are swapped.
2.3.1 Cochran–Armitage Trend Test (CATT)
The Cochran–Armitage test for trend (CATT) (Armitage, 1955; Cochran, 1954; Sasieni, 1997;
Slager and Schaid, 2001) is often used to test the null hypothesis (2) against one of the common
(recessive, additive, dominant) genetic models (alternative hypotheses) in (4). It is based on
the statistic
∑2
i=0 si(xi/n1 − yi/n2), where s0, s1, s2 are scores appropriate for the alternative
hypothesis in question. Standardizing and replacing unknown parameters pi, qi by estimators
mi/N , we obtain the CATT test statistic,
CATT =
∑2
i=0 si(n2xi − n1yi)√
n1n2
(∑2
i=0 s
2
imi − 1N
(∑2
i=0 simi
)2) ,
which asymptotically has a standard normal distribution under the null hypothesis. The ab-
solute value of CATT is invariant to linear transformations of the scores, so they are chosen
(s0, s1, s2) = (0, s, 1), and we use the notation CATTs for CATT with those scores. The value of
s is chosen as s = 0, 1/2, 1 for the recessive, additive and dominant model of (4), respectively
(Zheng et al., 2003). The index s thus denotes which genetic model (alternative hypothesis) is
used. A large value of |CATTs| indicates rejection of the null hypothesis.
We will study the CATT1/2 test statistics further.
2.3.2 Pearson Chi-Squared Test (Pearson)
The well-known Pearson chi-squared test statistic
2∑
i=0
(
(xi −min1/N)2
min1/N
+
(yi −min2/N)2
min2/N
)
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is not tailored to be powerful for monotone genetic models (3) in particular but rather to
test against the more general alternative that f0, f1 and f2 are not all equal. Under the null
hypothesis, the Pearson test statistic for our 2×3 situation asymptotically follows a chi-squared
distribution with two degrees of freedom. A large value indicates rejection of the null hypothesis.
2.3.3 Minimum p-Value Test (MIN2)
The statistic MIN2 is defined as the minimum of the asymptotic p-values of CATT1/2 and of
the Pearson chi-squared statistic. It is not a valid p-value itself, but its asymptotic distribution
under the null hypothesis is given by
Pr(MIN2 ≤ t)→ 1
2
t+
1
2
e−q/2 − 1
2pi
∫ −2 ln t
q
e−v/2 arcsin
(2q
v
− 1
)
dv,
where q is the 1−t quantile of the chi-squared distribution with one degree of freedom (Joo et al.,
2009). A small value of MIN2 indicates rejection of the null hypothesis.
2.3.4 Maximum test (MAX3)
The statistic MAX3 = max(|CATT0|, |CATT1/2|, |CATT1|) was proposed as an alternative to
CATT when the genetic model is unknown but monotone, with emphasis on the recessive, addit-
ive or dominant model (Freidlin et al., 2002). Asymptotically, CATT1/2 is a linear combination
of CATT0 and CATT1, and (CATT0,CATT1) has a bivariate normal asymptotic distribution
(Zang et al., 2010). The asymptotic p-value of MAX3 can be found as the probability of a bivari-
ate normal pair lying outside a region, which is in general hexagonal, in the plane. Specifically,
Pr(MAX3 ≥ t)→ 1− 2
∫ (1−ω1)t/ω0
0
φ(x)
(
Φ
(
t− ρx√
1− ρ2
)
− Φ
(−t− ρx√
1− ρ2
))
dx
− 2
∫ t
(1−ω1)t/ω0
φ(x)
(
Φ
(
(t− ω0x)/ω1 − ρx√
1− ρ2
)
− Φ
(−t− ρx√
1− ρ2
))
dx,
where
ω0 =
√
g2(1− g2)
g0(1− g0) + g2(1− g2) + 2g0g2 and ω1 =
√
g0(1− g0)
g0(1− g0) + g2(1− g2) + 2g0g2
are the coefficients making CATT1/2 → ω0CATT0 + ω1CATT1 asymptotically,
ρ =
√
g0g2
(1− g0)(1− g2) (5)
is the asymptotic correlation coefficient of CATT0 and CATT1 under the null hypothesis (2),
and φ and Φ are the standard normal pdf and cdf, respectively (Zang et al., 2010). When the
asymptotic p-value is computed, g0, g1 and g2 must be replaced by their consistent estimators
m0/N , m1/N and m2/N , respectively.
2.3.5 Constrained Maximum Test (CMAX)
The Pearson chi-squared test statistic (Section 2.3.2) is equal to CATT2s, where the score is
determined by the data, s = (x1/m1 − x0/m0)/(x2/m2 − x0/m0) (Zheng et al., 2009), which
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can be viewed as an estimator for (f1 − f0)/(f2 − f0). Also, this is the s maximizing CATTs
(Zheng et al., 2009). This motivates a test statistic,
CMAX = max
0≤s≤1
CATTs =
{
Pearson if 0 < s < 1
max(CATT20,CATT
2
1) otherwise
(the second equality was shown by Zheng et al., 2009).
The distribution of CMAX can be seen as a mixture of the distribution of the Pearson
statistic and the distribution of max(CATT20,CATT
2
1), with weights w
′ = Pr(0 < s < 1) and
1 − w′, respectively. Applying a two-dimensional version of the central limit theorem to the
trinomial vector (x0, x1, x2), the asymptotic value of w
′ is found as the integral of a binormal
density over the region 0 < s < 1 in the (x0, x2) plane, giving w
′ → w = 1pi arccos ρ (see (5)).
Under the null hypothesis, the Pearson statistic has the chi-squared distribution with two degrees
of freedom, and the asymptotic distribution of (CATT0,CATT1) is standard binormal with
correlation ρ. The asymptotic p-value of CMAX is
Pr(CMAX ≥ t) = 1− wF (t)− 2(1 − w)
∫ √t
0
φ(x)
(
Φ
(√
t− ρx√
1− ρ2
)
−
(−√t− ρx√
1− ρ2
))
dx,
where φ and Φ are the standard normal pdf and cdf, respectively, and F the cdf of the chi-
squared distribution with two degrees of freedom. Again, g0, g1 and g2 enter into ρ, and must
be replaced by their consistent estimators m0/N , m1/N and m2/N , respectively, to compute
an asymptotic p-value.
2.3.6 Constrained Likelihood Ratio Test (CLRT)
CLRT is the likelihood ratio test statistic, but the maximum under the alternative hypothesis
is taken under the constraint of the genetic model being monotone (see Section 2.2). The log
likelihood given by the data from the two independent trinomial distributions is
l = constant +
2∑
i=0
xi ln pi +
2∑
i=0
yi ln qi.
It is maximized by pi = xi/n1 and qi = yi/n2, giving a maximum (omitting the constant)
l1 = x0 lnx0 + x1 lnx1 + x2 lnx2 + y0 ln y0 + y1 ln y1 + y2 ln y2 − n1 lnn1 − n2 lnn2.
Under the constraint of a recessive model, f0 = f1, or equivalently, p0/q0 = p1/q1, the maximum
is obtained at
(pi, qi) =
mi
m0 +m1
(
x0 + x1
n1
,
y0 + y1
n2
)
, i = 0, 1 and p2 =
x2
n1
, q2 =
y2
n2
,
which gives the maximum
lrec = (x0 + x1) ln(x0 + x1) + x2 lnx2 + (y0 + y1) ln(y0 + y1) + y2 ln y2
+m0 lnm0 +m1 lnm1 − (m0 +m1) ln(m0 +m1)− n1 lnn1 − n2 lnn2.
Similarly, under the constraint of a dominant model, f1 = f2, or equivalently, p1/q1 = p2/q2,
the maximum is obtained at
p0 =
x0
n1
, q0 =
y0
n2
and (pi, qi) =
mi
m1 +m2
(
x1 + x2
n1
,
y1 + y2
n2
)
, i = 1, 2,
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which gives the maximum
ldom = x0 lnx0 + (x1 + x2) ln(x1 + x2) + y0 ln y0 + (y1 + y2) ln(y1 + y2)
+m1 lnm1 +m2 lnm2 − (m1 +m2) ln(m1 +m2)− n1 lnn1 − n2 lnn2.
Under the null hypothesis (2), the maximum is obtained at pi = qi = mi/N , giving the maximum
l0 = m0 lnm0 +m1 lnm1 +m2 lnm2 −N lnN.
Then
CLRT =
{
−2(l1 − l0) if 0 ≤ s ≤ 1
−2(max(lrec, ldom)− l0) otherwise,
where s is the data-driven score defined in Section 2.3.5. This is the same statistic as obtained
by Wang and Sheffield (2005), who showed that CLRT has the same asymptotic distribution
under the null hypothesis as described for CMAX (Section 2.3.5).
2.3.7 Maximin Efficiency Robust Test (MERT)
Amaximin efficiency robust test (Gastwirth, 1985) can be constructed from CATT0 and CATT1,
giving MERT = (CATT0 + CATT1)/
√
2(1 + ρ), where ρ is defined in (5) (Zheng et al., 2006).
It has an asymptotic standard normal distribution under the null hypothesis. A large value of
|MERT| indicates rejection of the null hypothesis.
2.4 Using Conditional Enumeration to Calculate p-Values
When an outcome z = (x0, x1, x2, y0, y1, y2), is presented as a contingency table (Table 1) the
column margins are m0 = x0 + y0, m1 = x1 + y1 and m2 = x2 + y2. When we condition on the
column margins M(z) = (m0,m1,m2), the probability under the null hypothesis of an outcome
z is a trivariate hypergeometric probability
Pr(Z = z |M(Z) =M(z)) =
(m0
x0
)(m1
x1
)(m2
x2
)(N
n1
) , (6)
showing that the column margins are sufficient statistics for the genotype frequencies, which
would otherwise be nuisance parameters. Any test statistic T (with, say, large values indicating
rejection of the null hypothesis) defines a p-value of an outcome z conditioned on its column
margins M(z). It can be calculated by the sum
p(z) = Pr(T (Z) ≥ T (z) |M(Z) =M(z)) =
∑
T (z′)≥T (z)
Pr(Z = z′ |M(z′) =M(z)). (7)
The number of summands in (7) is much smaller than it would have been without conditioning,
making summation also feasible for relatively large studies. Bakke and Langaas (2012) found a
formula for the maximum number of summands in (7). For unbalanced sample sizes where n2 ≥
2n1 the maximum number of summands is simply
(n1+2
2
)
. Numerical examples are presented in
Table 2.
We have seen that the outcome of an experiment can be presented as a contingency table
z = (x0, x1, x2, y0, y1, y2). The outcome may alternatively be given on the individual level as
two vectors of length N , one giving the disease status and one giving genotype status. Thus,
entry l in the disease vector gives the disease status of individual l and entry l in the genotype
vector gives the coded genotype of individual l. In permutation testing we generate b new
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Table 2: Maximum number N∗ of tables with given column margins for sample size n1 cases
and n2 controls. This will be the maximum number of summands when calculating the exact
conditional enumeration p-value in Equation (7). The notation ≥ i means that N∗ is the same
for all n2 ≥ i.
n1 500 500 1000 1000 5000 5000
n2 500 ≥1000 1000 ≥2000 5000 ≥10000
N∗ 83834 125751 334334 501501 8338334 12507501
outcomes of our experiment by permuting (shuffling) the genotypes vector, while keeping the
disease vector fixed. This gives b new contingency tables with the same margins as the observed
contingency table. The permutation p-value is given as the proportion of the b + 1 outcomes
(the original outcome and the b permutation outcomes) having a value of the test statistic
T greater than or equal to that of the original outcome. The permutation p-value is valid
(Phipson and Smyth, 2010). When b tends to infinity the permutation p-value equals the exact
conditional enumeration p-value. This can be seen by the fact that the permutation procedure
is a trivariate hypergeometric experiment, drawing genotypes of the n1 cases from the m0, m1,
m2 of each genotype. Moldovan and Langaas (2013) show in a worked-through example how to
calculate the exact conditional enumeration p-value using the MAX3 test statistic.
We recommend using the exact conditional enumeration p-value, and not the simulated
permutation p-value, based on the following arguments. If the permutation algorithm is run more
than once for the same observed outcome, this may result in a different simulated permutation
p-value for each run, which for a given significance level may lead to different hypothesis testing
decisions. For GWA studies a significance level of 5 · 10−8 is routinely used. To be able to arrive
at a p-value below this significance level b must at least be 2 · 107. Using permutation with
very large values of b is very inefficient compared to using (7) directly, as can also be seen from
Table 2.
2.5 Validity of p-values
For a chosen significance level α and an outcome z, the null hypothesis is rejected if the p-value
p(z) ≤ α. For a test to keep its size, the probability of rejection under the null hypothesis should
be less than or equal to α, i.e. Pr(p(Z) ≤ α) ≤ α for all α and all parameters under the null
hypothesis. Such a p-value is called valid (Casella and Berger, 2001, p. 397).
When calculating a p-value based on the asymptotic distribution of a test statistic, there
is no reason to believe that this will be a valid p-value for the sample size under study. The
conditional p-value defined in Section 2.4, is on the other hand always valid, not only considered
as a p-value when the experiment is conditioned on M(Z), but also considered as a p-value for
the original experiment (here case–control) (Casella and Berger, 2001, p. 399).
2.6 Power
Desirable properties of a p-value are validity and high power (the probability to reject H0). If
the sample space is discrete, the power at a parameter vector θ of a test defined by p(Z) for a
given α is
γ(θ) = Prθ(p(Z) ≤ α) =
∑
p(z)≤α
Prθ(Z = z), (8)
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where the probabilities depend on the parameter vector θ, and the summation is over all out-
comes z having a p-value not greater than α. The test size is supθ∈Θ0 γ(θ), where the supremum
is taken over all parameter vectors under the null hypothesis.
In our set-up, explained in detail in Section 3, the number of summands in (8) is maximally(
n1+2
n1
)(
n2+2
n2
)
, which becomes too large for practical use for the sample sizes we consider. We
instead estimate test size and power using simulation. We base our calculations on b independent
random draws from the probability distribution for the data (1). Let p(zi) be the calculated
p-value for drawing i. Then the estimated power, γ̂(θ), is
γ̂(θ) =
1
b
b∑
i=1
I[0,α](p(zi)), (9)
where I is the indicator function having value 1 if p(zi) ≤ α and 0 otherwise. That is, the power
(or test size) is estimated as the fraction of p-values below α for the b independent random
draws from the parameter vector θ.
3 A study on test size and power
We will now investigate size and power using p-values from the asymptotic approximations and
the exact conditional enumeration for the seven statistics from Section 2.3 in various settings.
3.1 Set-up
In most genetic association studies the number n1 of cases does not exceed the number n2
of controls. We will also make this assumption. We consider both balanced and unbalanced
designs. For n1 equal to 500 or 1000, we consider n2 to be 1, 2, 3, 4, 5 times n1. For n1 = 5000,
we consider n2 to be 1, 2, 3 times n1. This gives in total 13 sample sizes (n1, n2) to consider.
Our data generation procedure is inspired by Joo et al. (2009). We have studied a disease
prevalence of 10%, since genetic association studies in general are designed to target common dis-
eases. Most GWA studies are based on single nucleotide polymorphisms (SNPs) with minor allele
frequency (MAF) at least 5%. We have chosen a MAF of 10%, and we only consider populations
under Hardy–Weinberg equilibrium, which gives genotype frequencies g0 = (1−MAF)2 = 0.81,
g1 = 2MAF(1−MAF) = 0.18, g2 = MAF2 = 0.01. We assume that the minor allele is also the
disease allele. For each situation under study we calculate θ = (p0, p1, p2, q0, q1, q2) based on the
formulas in Section 2.2, and draw data based on the probability distribution (1).
Under the null hypothesis of equal penetrances for the genotypes, we draw 4 · 109 samples
from the study population. For this number of simulated samples we will for a valid test at
significance level 5 · 10−8 get an approximate 95% confidence interval for the test size that have
half-length 1.96 ·
√
5 · 10−8 · (1− 5 · 10−8)/(4 · 109) = 7 · 10−9.
We also study populations under alternative hypotheses, as presented in Section 2.2. Para-
meters chosen for the alternative hypotheses are the genotype relative risk λ2 = 1.1, 1.2, 1.5,
2 and the genetic model parameter δ = 0, 1/4, 1/2, 3/4, 1. The genotype relative risk λ1 is
calculated from δ and λ2 using (3).
For all the possible combinations for λ2 and δ (as given above), and for each of the 13 sample
sizes we drew one million random samples from the population described by these parameter
values. This resulted in 4 · 5 · 13=260 situations. With this number of samples we will for a true
power of 0.8 achieve an approximate 95% confidence interval for the power with half-length
1.96 ·
√
0.8 · (1− 0.80)/(1 · 106) = 8 · 10−4.
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For each sample drawn we calculated the asymptotic and the exact conditional enumeration
p-values for the seven test statistics (CATT1/2, Pearson, MIN2, MAX3, CMAX, CLRT and
MERT) under study, and estimated the test size or power as the relative number of p-values
falling below the significance levels investigated (9).
For evaluation of test size and power we present results for significance levels α in the range
5 · 10−2 to 5 · 10−8.
3.2 Computational details
The numerical calculations were performed in the C++ language of the GNU Compiler Collec-
tion 4.4.3. For generating multinomial vectors, making statistical distribution calculations and
numerical integration, the GNU Scientific Library 1.13 was used. To reduce computation time,
the parallel language extension OpenMP was used to distribute the generation of tables and
subsequent statistical calculations among several threads operating on different processors.
For the asymptotic method, power calculations in the case of CATT1/2, Pearson, MIN2 and
MERT were done by comparing test statistics for simulated data with critical values, which is
faster than calculating p-values explicitly. In the case of MAX3, CMAX and CLRT, p-values
depend on estimated parameters, and had to be calculated for each simulated table.
For the exact conditional enumeration method, to avoid numerical overflow, the hypergeo-
metric probabilities (6) were calculated by adding logarithms of factorials and then taking the
antilogarithm. To gain speed, the ln l! were computed once and tabulated for l = 0, 1, . . . , N .
If, for a simulated table (x0, x1, x2, y0, y1, y2), during the evaluation of the exact conditional
enumeration p-value (7), the sum for all seven statistics T had exceeded the highest significance
level considered, 0.05, the evaluation was aborted, since the table would then not contribute to
the power. Also, to speed up the time for a possible early abortion of the summation (7), the
summation was started at tables potentially having a high conditional probability (6), namely
those having x0 as the upper left entry. Then tables having x0 + 1 as the upper left entry
were considered and so on upwards, and thereafter the process was repeated going from x0 − 1
downwards.
For the largest sample size considered in the simulation study, (5000, 15000), the maximum
number of summands in the calculation of the exact conditional enumerations p-value is 12.5
million. This maximum number will occur for tables having equal or nearly equal column mar-
gins. However, our choice of MAF = 0.1 will with very low probability give such balanced column
margins. On a 4× 6-core Xeon 2.67 GHz computer (Intel CPU) running Linux (Ubuntu 10.4),
using one tread, the computation of exact conditional enumeration p-values for 1000 tables with
sample size n1 = 5000 and n2 = 15000 drawn from the null hypothesis took under 14 seconds.
The corresponding computation for 1000 such tables drawn under an alternative hypothesis
having power near 100% for all test statistics, took under two minutes. Calculation of the exact
conditional enumeration p-value is faster when tables are drawn from the true null hypothesis
than when tables are drawn from the alternative hypothesis. This is due to the fact that p-value
calculated for tables generated under the true null are in general larger than p-values for tables
generated under the alternative hypothesis, and that we abort the calculations when the p-value
exceeds 0.05.
For smaller sample sizes, computations are much faster. For n1 = 1000, n2 = 1000 the
timings are 2 seconds for the null hypothesis and 0.3 seconds for the alternative.
3.3 Effect of significance level and sample size
In Section 2.5 we pointed out that there is no guarantee that asymptotic methods preserves the
test size, while the exact conditional methods are always valid by construction. However, for
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α = 0.05 we found that the asymptotic methods for nearly all test statistics (except CLRT) kept
the test size for all sample sizes investigated. With the exception of CLRT we get an increasing
degree of mismatch between the observed and the nominal level for the asymptotic methods
when α decreases to 5 · 10−8. Worst are MAX3 and CMAX for small and unbalanced designs,
with test size up to 20 times the nominal level. For low significance levels, MAX3, Pearson,
MIN2, MERT and CMAX keeps under 1.2 times the nominal level only for balanced designs
and for designs having the number of controls twice the number of cases. CATT1/2 fares a little
better, but at worst has size twice the nominal level, and CLRT is always within 1.5 times the
level. In Table 3 we present estimated test sizes for balanced sample sizes for the asymptotic
and exact conditional methods for all seven test statistics for three values of the significance
level (low, 5 · 10−2; intermediate, 5 · 10−5; high, 5 · 10−8). To emphasize the need to use exact
conditional methods instead of asymptotic methods for low significance levels and unbalanced
sample sizes Table 4 gives test sizes for significance level 5 · 10−8 for the asymptotic method.
Turning to the power study, we find that the power increases with increasing sample sizes
and with increasing significance levels. This can be seen in Table 5 (the effect of significance
level) and 6 (the effect of sample size). Keeping the total sample size fixed the highest power is
observed for balanced sample sizes and decreases with increasing degree of unbalance. This can
be observed (Table 6) for the sample size combinations (n1, n2) = (500, 1500) and (1000, 1000),
both giving total sample size 2000, and this is also the case for (500, 2500) and (1000, 2000),
with total sample size 3000.
3.4 Effect of genetic model
Since the asymptotic methods, with CLRT as the exception, are in general not valid, we base
our discussion on comparing power based on the exact conditional enumeration p-values. But,
the power of the invalid asymptotic methods will in general not be substantially larger than the
power of the valid exact conditional methods, which is seen in Tables 5–8.
We have chosen to only study monotone genetic models, and we find that the effect of genetic
model seem to be similar for all sample sizes and significance levels. Results for (n1, n2) =
(5000, 15000) and α = 5 · 10−6 are shown in Table 7.
For the recessive model (δ = 0) the CMAX and MAX3 methods performs the best (with
very similar powers). The CATT1/2 performs poorly for the recessive model, as compared to
all the other test statistics studied. The most extreme situation observed was for sample size
(5000,15000) for λ2 = 2 and α = 5 · 10−6, where CATT1/2 gives a power of 4.6% while the
CMAX gives a power of 88.4% (Table 7, fourth row from the top).
For the semi-recessive model (δ = 1/4) MERT gives the best performance (Table 7, rows
5–8).
For the additive model (δ = 1/2) the CATT1/2 performs the best. This is also true for the
semi-dominant (δ = 3/4) and the dominant (δ = 1) models. The MERT test statistic has for
these three genetic models lower power than the other test statistics. The other test statistics
(Pearson, MIN2, MAX3, CMAX and CLRT) have comparable powers, in most cases slightly
lower than CATT1/2 and higher than MERT (Table 7, lower part; Table 5 for the additive
model).
3.5 General findings
From the results of our power study we may divide the test statistics into four groups based
on their overall performance. (i) The CATT1/2 has very good performance for all models other
than the recessive, (ii) MERT performs well for the semi-recessive model, but else has a less
good performance, (iii) the three test statistics MAX3, CMAX and CLRT have very similar
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Table 3: Scaled test size for test statistics, methods (A asymptotic, C exact conditional), balanced sample sizes and selected significance
levels α. The test sizes shown are scaled by multiplying by 5/α, so that 5.00 will give an exact test. The test size estimate is based on 4 · 109
simulations, giving 95% confidence interval half-lengths of 6.8 · 10−6, 2.2 · 10−7, 6.9 · 10−9 for true test sizes 5 · 10−2, 5 · 10−5, 5 · 10−8,
respectively
CATT1/2 Pearson MIN2 MAX3 CMAX CLRT MERT
n1 n2 α A C A C A C A C A C A C A C
500 500 5 · 10−2 5.00 4.21 4.78 4.91 4.77 4.66 4.75 4.14 4.62 4.73 5.43 4.55 4.93 4.81
5 · 10−5 4.53 3.66 2.28 4.82 3.24 4.13 2.61 4.20 2.04 4.64 5.38 4.59 2.08 4.46
5 · 10−8 3.15 2.95 1.20 4.80 2.02 3.42 1.85 3.42 1.05 3.98 3.02 3.88 0.15 3.98
1000 1000 5 · 10−2 5.00 4.42 4.89 4.96 4.90 4.76 4.85 4.39 4.64 4.80 5.00 4.80 4.98 4.91
5 · 10−5 4.76 4.02 3.06 4.96 3.73 4.48 3.10 4.45 2.75 4.87 6.19 4.70 3.36 4.80
5 · 10−8 4.83 4.35 1.92 5.22 3.20 4.67 2.77 4.62 1.77 5.10 6.42 4.45 1.07 4.85
5000 5000 5 · 10−2 5.00 4.73 4.98 4.99 4.98 4.90 4.97 4.71 4.76 4.93 4.81 4.93 5.00 4.98
5 · 10−5 4.95 4.53 4.52 4.99 4.68 4.82 4.57 4.58 4.29 4.95 4.95 4.92 4.65 4.96
5 · 10−8 4.53 3.80 4.10 5.03 3.70 4.05 3.58 4.33 3.20 4.67 4.95 4.70 4.12 5.00
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Table 4: Scaled test size for test statistics, balanced and unbalanced sample sizes for the asymp-
totic method for significance level α = 5 · 10−7. The test sizes shown are scaled by multiplying
by 5/α, so that 5.00 will give an exact test. 4 · 109 simulations are run, giving 95% confidence
interval half-lengths of 2.2 · 10−8 for true test sizes 5 · 10−7.
n1 n2 CATT1/2 Pearson MIN2 MAX3 CMAX CLRT MERT
500 500 3.81 1.61 2.55 2.28 1.50 3.66 0.54
1000 5.14 4.02 4.37 4.05 4.20 5.05 4.57
1500 6.01 14.81 11.78 17.52 15.12 4.32 11.80
2000 6.89 28.76 21.76 33.46 32.90 3.99 18.44
2500 7.60 42.75 31.05 50.29 46.66 4.01 23.97
1000 1000 4.55 2.19 3.30 2.71 1.95 6.83 1.78
2000 5.15 5.76 5.46 6.12 5.75 5.97 5.46
3000 5.35 11.84 9.54 12.33 12.82 5.31 9.04
4000 5.89 17.95 13.99 21.49 20.25 5.14 12.17
5000 6.22 23.74 17.95 26.95 26.23 5.13 14.90
5000 5000 4.85 4.01 4.29 4.06 3.75 5.05 4.13
10000 5.10 5.21 5.18 5.45 5.42 4.97 5.31
15000 5.23 6.84 6.30 7.27 7.23 5.11 6.21
performance and give good results for all genetic models, and lastly, (iv) Pearson and MIN2
also have very similar performance, in general slightly less powerful than the previous group,
but is also known to work well for non-monotone genetic models (Joo et al., 2009).
In Table 8 we present powers for α = 5 · 10−8 for all the sample sizes under study. For
each sample size we have chosen the genetic model and effect size that give power (over all
test statistics) closest to 80%. These results are influenced by a selection bias due to the fact
that for small sample sizes only the dominant models with large effects sizes will achieve power
near 80%, and for large sample sizes power near 80% will be achieved for additive to recessive
models. Taking this into mind, we see that the general results presented above are reflected in
this table. To summarize, the exact conditional enumeration method and the MAX3 test stat-
istics is the most powerful for small balanced and slightly unbalanced sample sizes, (500, 500),
(500, 1000) and (1000, 1000), for the dominant model. For (500, 1000), the MAX3 test statistics
(exact conditional enumeration) gives 46.6 percentage points higher power than the MERT test
statistic. For the unbalanced sample sizes, (500, 1500), (500, 2000), (500, 2500), (1000, 2000),
(1000, 3000), (1000, 4000), (1000, 5000), the asymptotic method for the MAX3 test statistic is
the most powerful for the dominant and semi-dominant model. This is not surprising since the
asymptotic MAX3 shows large violations for these unbalanced sample sizes. For this reason,
we do not recommend using the asymptotic method for these test statistics for unbalanced
sample sizes. Only considering the exact conditional enumeration method for these unbalanced
sample sizes, the best performance is found for the CATT1/2 test statistics. For the largest
sample sizes, MERT performs the best for the semi-recessive model for (5000, 5000), while the
CATT1/2 performs the best for the large unbalance sample sizes (5000, 10000), (5000, 15000)
under the additive model.
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Table 5: Power: Effect of test statistic, method (A asymptotic, C exact conditional) and significance level (α). Sample size is (n1, n2) =
(5000, 5000), genetic model is additive (δ = 0.5) and genetic relative risk λ2 = 1.5.
CATT1/2 Pearson MIN2 MAX3 CMAX CLRT MERT
α A C A C A C A C A C A C A C
5 · 10−2 100.0 100.0 99.9 99.9 100.0 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.8 99.8
5 · 10−3 99.5 99.5 98.8 98.8 99.3 99.3 99.2 99.2 99.1 99.2 99.1 99.1 97.8 97.8
5 · 10−4 97.2 97.1 94.6 94.7 96.4 96.4 96.0 96.1 95.7 95.9 95.7 95.7 90.8 90.9
5 · 10−5 91.0 90.6 85.3 85.7 89.1 89.1 88.4 88.7 87.4 88.0 87.5 87.6 77.4 77.8
5 · 10−6 79.6 79.1 71.0 71.8 76.7 76.8 75.8 76.4 74.1 75.3 74.3 74.3 59.4 60.2
5 · 10−7 64.4 63.7 54.0 55.4 60.8 61.2 59.8 60.9 57.7 59.5 58.0 58.0 41.0 42.1
5 · 10−8 47.6 47.0 37.5 39.2 44.0 44.6 43.1 44.5 41.0 43.1 41.3 41.2 25.5 26.7
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Table 6: Power: Effect of test statistic, method (A asymptotic, C exact conditional) and sample size (n1 cases, n2 controls). The genetic
model is semi-dominant (δ = 3/4), genetic relative risk λ2 = 1.5 and significance level α = 5 · 10−5.
CATT1/2 Pearson MIN2 MAX3 CMAX CLRT MERT
n1 n2 A C A C A C A C A C A C A C
500 500 3.9 3.5 2.3 3.3 3.2 3.5 3.1 3.9 2.7 3.9 3.0 2.8 1.4 2.0
1000 9.9 9.2 6.9 7.1 8.6 8.4 8.4 8.4 7.7 7.9 6.7 6.5 4.4 4.6
1500 14.1 12.9 10.4 8.6 12.5 10.6 12.3 10.1 11.4 9.3 9.2 9.5 6.6 5.8
2000 16.9 15.6 13.0 9.5 15.3 11.9 15.1 10.9 14.1 10.1 11.1 11.5 8.3 6.7
2500 19.0 17.3 14.7 10.0 17.2 12.7 17.0 11.3 16.0 10.5 12.3 12.8 9.4 7.2
1000 1000 21.6 20.5 15.6 17.9 19.1 19.9 19.1 21.1 17.2 20.1 17.8 16.8 8.7 9.9
2000 42.4 41.2 34.6 34.6 39.3 38.7 39.3 38.9 36.9 37.3 34.8 33.7 20.9 21.2
3000 52.8 51.3 44.9 42.1 49.7 47.2 49.8 46.4 47.4 44.4 44.0 42.5 28.0 26.9
4000 58.7 57.3 51.2 46.5 55.9 52.1 56.0 50.7 53.7 48.7 49.5 47.8 32.7 30.5
5000 62.5 61.0 55.2 49.4 59.8 55.0 59.9 53.4 57.6 51.3 53.1 51.2 35.8 32.8
5000 5000 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 98.0 98.0
10000 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 99.9 99.9
15000 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
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Table 7: Power: Effect of test statistic, method (A asymptotic, C exact conditional), genetic model (δ = 0 recessive, δ = 1 dominant) and
genetic relative risk (λ2). Sample size is (n1, n2) = (5000, 15000) and significance level α = 5 · 10−6.
CATT1/2 Pearson MIN2 MAX3 CMAX CLRT MERT
δ λ2 A C A C A C A C A C A C A C
0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
1.2 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0
1.5 0.1 0.1 7.6 7.2 6.3 6.1 8.6 7.5 8.2 7.7 5.4 5.4 2.8 2.7
2 4.7 4.6 88.2 87.6 86.2 85.7 89.8 88.5 89.1 88.4 84.6 84.6 60.5 59.9
0.25 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
1.2 0.3 0.2 0.2 0.2 0.3 0.2 0.2 0.2 0.3 0.3 0.2 0.2 0.4 0.4
1.5 34.9 34.3 33.7 32.5 35.3 34.3 30.8 29.1 37.2 36.0 33.4 33.5 41.5 40.8
2 99.9 99.9 99.9 99.9 100.0 100.0 99.9 99.9 100.0 100.0 99.9 99.9 100.0 100.0
0.5 1.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
1.2 4.3 4.2 2.7 2.5 3.6 3.4 3.3 3.0 3.2 3.0 2.8 2.8 2.5 2.4
1.5 98.3 98.2 96.8 96.5 97.8 97.7 97.6 97.4 97.4 97.2 97.0 97.0 92.1 91.8
2 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
0.75 1.1 0.6 0.5 0.3 0.3 0.5 0.4 0.4 0.4 0.4 0.4 0.3 0.3 0.2 0.2
1.2 25.6 25.1 19.7 18.7 23.2 22.3 23.4 22.1 21.5 20.5 20.0 20.0 10.2 9.9
1.5 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 99.9 99.8
2 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
1 1.1 2.3 2.2 1.6 1.5 2.0 1.9 2.1 1.8 1.7 1.6 1.5 1.5 0.7 0.6
1.2 64.7 64.1 59.9 58.5 63.2 62.0 64.6 62.9 61.6 60.2 59.7 59.8 27.7 27.1
1.5 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
2 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
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Table 8: Power: Effect of test statistic, method (asymptotic, A, and exact conditional, C) and sample size (n1 cases, n2 controls) for significance
level α = 5 · 10−8. Values of the genetic model δ and λ2 are chosen to give power closest to 80%. For each sample size the most powerful
combination of method and test statistic is given in bold face, while the most powerful exact conditional enumeration method and test
statistic is given in italic.
CATT1/2 Pearson MIN2 MAX3 CMAX CLRT MERT
n1 n2 δ λ2 A C A C A C A C A C A C A C
500 500 1 2.0 36.8 36.0 32.3 39.2 35.3 38.0 37.5 41.2 34.2 41.4 36.0 37.3 7.5 14.0
1000 1 2.0 74.1 72.3 71.6 72.6 73.8 73.6 75.7 76.1 73.1 73.8 69.8 69.7 29.5 29.4
1500 1 2.0 86.2 83.8 84.9 78.2 86.2 80.9 87.6 82.1 85.8 79.0 81.9 82.7 43.8 36.0
2000 1 2.0 91.0 88.7 90.2 79.9 91.1 83.0 92.1 82.8 90.9 80.1 87.3 88.0 52.4 39.8
2500 1 2.0 93.4 91.2 92.9 81.0 93.6 84.0 94.3 82.8 93.4 81.1 90.1 90.8 57.9 42.4
1000 1000 0.75 2.0 68.4 67.6 62.0 67.1 66.3 68.1 67.7 70.8 64.7 70.3 65.8 63.6 28.7 34.8
2000 0.75 2.0 93.8 93.4 91.8 91.4 93.3 92.8 93.8 93.2 92.8 92.3 91.6 91.2 65.1 64.1
3000 0.75 2.0 97.8 97.4 97.0 95.2 97.6 96.4 97.9 96.3 97.4 95.6 96.6 96.5 78.8 74.1
4000 0.75 2.0 98.9 98.6 98.5 96.6 98.8 97.5 98.9 97.3 98.7 96.8 98.1 98.1 85.0 79.0
5000 0.75 2.0 99.3 99.1 99.0 97.3 99.3 98.1 99.4 97.9 99.2 97.5 98.7 98.8 88.3 81.9
5000 5000 0.25 2.0 81.5 81.1 78.6 79.7 80.7 81.1 77.1 78.0 81.3 82.6 82.0 82.0 83.0 83.8
10000 0.50 1.5 80.3 79.9 72.7 71.9 77.8 77.1 77.1 76.1 75.5 74.7 73.8 73.8 57.8 57.3
15000 0.50 1.5 89.6 89.2 84.5 82.5 88.0 86.7 87.5 85.4 86.5 84.4 84.7 84.7 71.6 69.9
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4 Discussion
Parameter choices in the simulation study In the simulation study (Section 3) all data
have been generated assuming that the disease prevalence is k = 0.1, the minor allele (disease
allele) frequency is MAF = 0.1, and that the total population is in Hardy–Weinberg equilibrium
(HWE). Further, we have only studied monotone genetic models with low to moderate effects
size λ2 and sample sizes in the order 500–5000 cases and 500–15000 controls. The conclusions
to be drawn from the simulations study are thus only valid for these situations. However, some
observations on the effect of changes to the set-up may be drawn.
The data are simulated in a case–control design. Keeping all other parameters fixed, the effect
of doubling the disease prevalence is to double the probability of disease for each genotype.
This will leave the genotype probabilities for the cases unchanged, and will only change the
genotype probabilities for the controls slightly. We believe that the effect of changing the disease
prevalence in our study will be minor.
There is a straightforward effect of changing the MAF. The simulation study used MAF =
0.1, and lowering the MAF will, most importantly, lead to a lower probability for the disease
type homozygotes, g2 = MAF
2. This will in turn lead to a greater imbalance in the expec-
ted cell counts for the six contingency table cells, influencing the validity of the asymptotic
approximations in a negative manner.
Since we are working with test statistics that are based on genotype data, there is no need
to assume HWE. We may generate data deviating from HWE by introducing an inbreeding
coefficient when calculating genotype frequencies. In a data model with positive inbreeding
coefficient the genotype frequencies for the two groups of homozygotes will increase and the
genotype frequency for the heterozygote will decrease. We believe this will influence the disease
homozygote group the most, and that this in turn will lead to a better balance in the expected
cell counts for the six contingency table cells, thus, influencing the asymptotic approximations
in a positive manner.
Validity and asymptotic methods For candidate studies and intermediate follow-up stud-
ies producing a p-value for each genetic marker is in general of interest, while for GWA studies
the main objective may be to provide a ranking of the genetic markers (with respect to increasing
strength of the disease–genotype association).
We first discuss ranking of test statistics and ranking of p-value for GWA studies. Assume
that in a case–control study with n1 cases and n2 controls we have studied m genetic markers.
These markers may in general come from a population with different genotype frequencies for
each marker. The collected data would typically have different column margins.
For the test statistics CATT1/2, Pearson, MIN2 and MERT, the asymptotic null distribution
of the test statistics does not depend upon any unknown parameters, and also not on n1 and n2.
This means that the rank of the m genetic markers according to each of these test statistics will
be the same as the rank according to the corresponding asymptotic p-value. For the test statistics
MAX3, CMAX and CLRT the asymptotic null distribution is dependent on the estimated value
of the genotype frequencies g0, g1, g2. The ranking of the genetic markers by test statistic
may differ from the ranking by the asymptotic p-values, but we believe that the difference in
ranking is minor. For the ranking of the test statistics as compared to the ranking of the exact
conditional enumeration p-value, the ranking of the exact conditional enumeration p-value will
only be the same as the ranking of the test statistic for genetic markers with identical column
margins. In a GWA study the ranking of the genetic markers based on a test statistic will be
different from the ranking based on exact conditional enumeration p-values. To which extent
the rankings differ may be a topic of further study.
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When a p-value is calculated and used to guide the acceptance or rejection of one or many
null hypotheses we would like to advocate using methods that produce valid p-values. Otherwise,
violations of the single or multiple type I error will lead to loss of type I error control, and to
optimistic power calculations.
The lack of validity of the p-values from asymptotic methods for low significance levels is
in general not surprising, and has for other test statistics been observed by Morris and Elston
(2011).
In our simulation study the expected cell counts under the null hypothesis were gin1 and gin2
for genotypes i = 0, 1, 2 for cases and controls, respectively, which gave the smallest expected
cell count of g2n1 = 0.01 · 500 = 5 over all our simulations. Thus, for all sample sizes studied
there are no expected cell counts below 5 under the null hypothesis.
The asymptotic p-value calculated from the Pearson test statistic has been studied extens-
ively. Cochran (1954) formulated the following rule of thumb for using the Pearson test statistic
with the asymptotic chi-squared approximation for contingency tables with more than one de-
gree of freedom (larger than 2 × 2). “If relatively few expectations are less than 5 (say in 1
cell out of 5 or more, or 2 cells out of 10 or more), a minimum expectation of 1 is allowable
in computing χ2.” However, we found that the asymptotic p-value for the Pearson test did not
keep its test size, especially for unbalanced sample sizes and low significance levels, even if all
cells had expected count at least 5.
Wise (1963) found that errors in the chi-squared approximation in a multinomial situation
are particularly small when the expected cell counts are equal or nearly so, and that these
expected cell counts need not be large. Our results point towards a greater effect of equality in
expected cells counts than of the numerical values of the expected cell counts. This can be seen
by comparing the test sizes in Table 4. For n1 = 500, observe that for the Pearson test statistics
(and also for the MIN2, MAX3, CMAX and MERT) the violations in test size increase as n2
increases from 500 to 2500. When n2 increases, the expected cell counts for the controls will
increase, but the difference between the expected cell counts between the cases and controls will
also increase. The same pattern is seen for n1 = 1000 as n2 increases.
In addition to the Pearson test statistics, the CATT1/2 and the MERT test statistics follow
the chi-squared and standard normal asymptotic null distributions. We believe that the obser-
vations on equality of expected cell counts for the Pearson test statistic will also apply to the
other test statistics.
Environmental covariates and logistic regression All the methods considered in this
presentation use only information on the disease phenotype and the genotype in order to calcu-
late test statistics and p-values. However, data on environmental covariates may also have been
collected. It is believed that complex diseases may be the result of an interplay between genetic
markers and environmental covariates.
The asymptotic CATTs test can be performed by first fitting a logistic regression to the
disease status as response and the genotype as covariates, where the value 0 is used as coding for
the wild type homozygotes, 1 for the disease homozygotes, and s for the heterozygotes, and then
performing an asymptotic score test. This strategy is easily extended to include environmental
covariates and interactions between environmental covariates and genotype. In a simulation
study Runde (2013) found that the power gain in including an environmental covariate (when
present) in a logistic regression score test is minimal compared to using the asymptotic CATTs
unless the effect of the (standardized) environmental covariate corresponds to a least an odds
ratio of 5.
Robust methods for disease–genotype association with covariates are available. So and Sham
(2011) has developed a MAX3 type method combining three asymptotic logistic regression
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score test. However, the validity of the method, in particular when using low significance levels,
has to our knowledge not been investigated. Exact conditional logistic regression are available
(Mehta and Patel, 1995), but to our knowledge exact methods have not been investigated for
robust methods with covariates.
5 Conclusions
We have studied seven test statistics that can be used to detect association between a dicho-
tomous phenotype (disease) and genotype. We advocate that if you work with GWA studies,
and would like to detect all monotone genetic models (including the recessive) with high power
you should not use the CATT1/2 test statistics, but instead work with MAX3, CMAX or CLRT.
If non-monotone effects are also of interest, the Pearson and MIN2 test statistics are found to
perform well, also for over- and under dominant models (Joo et al., 2009).
We have shown how exact conditional enumeration is a valid and powerful competitor to
simulated permutations and asymptotic approximation for producing p-values. Drawing simu-
lated permutations is an inefficient way of calculating an exact conditional enumeration p-value
for contingency tables of the size and order used in genetic association studies. In our simulation
study calculating exact conditional enumeration p-values was done in a fraction of a second,
even for the largest sample size considered in this presentation, (5000, 15000). Exact conditional
enumeration should therefore be preferred to simulated permutations.
Further, it should be well known that p-values based on asymptotic approximations need
not be valid, especially for small significance levels and unbalanced sample sizes, even when
expected cell counts are at least 5. In an extensive simulation study we have seen that for the
asymptotic approximation for the test statistics studied here, the violation of test size may be as
large as 20 times the nominal level. Lastly, the fact that exact conditional enumeration methods
give low power compared to asymptotic methods for small sample sizes for 2 × 2 contingency
tables due to discreteness (Lehmann, 1993), is not transferrable to 2× 3 contingency tables and
the test statistics and sample sizes under study. In conclusion we find that exact conditional
enumeration should also be preferred to asymptotic approximation, both with respect to test
size, power and computational considerations.
Software
A C++ program using the GNU Scientific Library that takes the entries of a 2 × 3 table as
input and gives the value of all seven test statistics together with the asymptotic and exact
conditional enumeration p-values is available upon request.
Conflict of Interest: None declared.
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